[
  {
    "Insurer":"Cigna",
    "HCPCS Code":"Q2055",
    "Active Ingredient":"Idecabtagene vicleucel",
    "Brand Name":"Abecma",
    "Therapeutic area":"Oncology",
    "indication":"Oncology",
    "indicated_population":"Multiple myeloma",
    "Label Population":"MM (RR, TCE, atleast four prior lines)",
    "clinical_criteria":"Abecma is considered medically necessary when the following are met:\n\nFDA-Approved indication\n1. Multiple Myeloma. Approve a single dose if the patient meets ALL the following (A, B, C, D, and E):\nA) Patient is \u2265 18 years of age; AND\nB) Patient meets ONE of the following (i or ii):\ni. Patient has received two or more lines of systemic therapy, including one therapy from each of the following (a, b, and c):\na) Patient has received an immunomodulatory agent; AND\nNote: Immunomodulatory agents include Thalomid (thalidomide capsules), lenalidomide capsules, Pomalyst (pomalidomide capsules).\nb) Patient has received a proteasome inhibitor; AND\nNote: Proteasome inhibitors include bortezomib injection, Kyprolis (carfilzomib intravenous infusion), Ninlaro (ixazomib capsules).\nc) Patient has received an anti-CD38 monoclonal antibody; OR\nNote: Anti-CD38 monoclonal antibodies include Darzalex (daratumumab intravenous infusion), Darzalex Faspro (daratumumab and hyaluronidase-fihj subcutaneous injection), Sarclisa (isatuximab-irfc intravenous infusion).\nii. Patient has received at least three prior lines of therapy; AND\nC) Patient has received or plans to receive lymphodepleting chemotherapy prior to infusion of Abecma; AND\nD) Patient has not been previously treated with chimeric antigen receptor T-cell (CAR-T) therapy; AND\nNote: Examples of CAR-T therapy includes Abecma, Carvykti (ciltacabtagene autoleucel intravenous infusion), Breyanzi (lisocabtagene maraleucel intravenous infusion), Kymriah (tisagenlecleucel intravenous infusion), Tecartus (brexucabtagene intravenous infusion), and Yescarta (axicabtagene intravenous infusion).\nE) The medication is prescribed by or in consultation with an oncologist.\n\nDosing. The dose of Abecma is up to 460 x 106 CAR-positive T-cells administered intravenous as a single dose.\n\nWhen coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.",
    "Prior Authorisation\/Medical necessity\/notification":"No",
    "Preferred product(s) required":null,
    "Site of care required":"No",
    "Exclusion Criteria":"Abecma for any other use is considered not medically necessary.",
    "Policy History\/Revision Information":"Annual Review Multiple Myeloma. 7\/1\/2024\nRemoved (1) 'Documentation of an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1', (2) 'Does not have central nervous system involvement with myeloma', (3) Does not have presence or history of plasma cell leukemia, (4) Removed Hematologist from specialist, (5) Documented diagnosis of multiple myeloma Conditions Not Covered.\nRemoved \u00e2\u20ac\u02dcRepeat administration of Idecabtagene vicleucel (Abecma), note that it was added to approve as a single dose in the criteria\nSelected Revision Multiple Myeloma: Requirement that the patient 8\/1\/2024\nhas received four or more lines of systemic therapy was revised to patient has received two or more lines of systemic therapy.\nAnnual Revision Multiple Myeloma: Added patient has received at 6\/1\/2025\nleast three prior lines of therapy as a new option for approval.\nUpdated HCPCS\/CPT Coding\nAdded code deleted note to CPT Codes: 0537T, 0538T, 0539T, 0540T (Codes deleted 12\/31\/2024)\nAdded CPT Codes: 38225, 38226, 38227, 38228\nUpdated the description for HCPCS Q2055 to match the 2024 revision.",
    "Conclusion":"Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy, indicated for the treatment of relapsed or refractory multiple myeloma in adults after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Cigna considers Abecma medically necessary for patients 18 years or older who have received at least two prior lines of systemic therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, or at least three prior lines of therapy, and who are planning to receive lymphodepleting chemotherapy prior to infusion of Abecma, and have not been previously treated with any CAR-T therapy. The medication must be prescribed by or in consultation with an oncologist. The dose of Abecma is up to 460 x 106 CAR-positive T-cells administered intravenously as a single dose. Abecma for any other use is considered not medically necessary. HCPCS code Q2055 and CPT codes 38225, 38226, 38227, and 38228 are associated with Abecma administration. The policy is currently active and was last updated on 2025-06-01.",
    "link":"https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0168_coveragepositioncriteria_idecabtagene_vicleucel.pdf"
  },
  {
    "Insurer":"Cigna",
    "HCPCS Code":"Q2055",
    "Active Ingredient":"Idecabtagene vicleucel",
    "Brand Name":"Abecma",
    "Therapeutic area":"Oncology",
    "indication":"Oncology",
    "indicated_population":"Multiple myeloma",
    "Label Population":"MM (RR, TCE, atleast two prior lines)",
    "clinical_criteria":"Abecma is considered medically necessary when the following are met:\n\nFDA-Approved indication\n1. Multiple Myeloma. Approve a single dose if the patient meets ALL the following (A, B, C, D, and E):\nA) Patient is \u2265 18 years of age; AND\nB) Patient meets ONE of the following (i or ii):\ni. Patient has received two or more lines of systemic therapy, including one therapy from each of the following (a, b, and c):\na) Patient has received an immunomodulatory agent; AND\nNote: Immunomodulatory agents include Thalomid (thalidomide capsules), lenalidomide capsules, Pomalyst (pomalidomide capsules).\nb) Patient has received a proteasome inhibitor; AND\nNote: Proteasome inhibitors include bortezomib injection, Kyprolis (carfilzomib intravenous infusion), Ninlaro (ixazomib capsules).\nc) Patient has received an anti-CD38 monoclonal antibody; OR\nNote: Anti-CD38 monoclonal antibodies include Darzalex (daratumumab intravenous infusion), Darzalex Faspro (daratumumab and hyaluronidase-fihj subcutaneous injection), Sarclisa (isatuximab-irfc intravenous infusion).\nii. Patient has received at least three prior lines of therapy; AND\nC) Patient has received or plans to receive lymphodepleting chemotherapy prior to infusion of Abecma; AND\nD) Patient has not been previously treated with chimeric antigen receptor T-cell (CAR-T) therapy; AND\nNote: Examples of CAR-T therapy includes Abecma, Carvykti (ciltacabtagene autoleucel intravenous infusion), Breyanzi (lisocabtagene maraleucel intravenous infusion), Kymriah (tisagenlecleucel intravenous infusion), Tecartus (brexucabtagene intravenous infusion), and Yescarta (axicabtagene intravenous infusion).\nE) The medication is prescribed by or in consultation with an oncologist.\n\nDosing. The dose of Abecma is up to 460 x 106 CAR-positive T-cells administered intravenous as a single dose.\n\nWhen coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.",
    "Prior Authorisation\/Medical necessity\/notification":"No",
    "Preferred product(s) required":null,
    "Site of care required":"No",
    "Exclusion Criteria":"Abecma for any other use is considered not medically necessary.",
    "Policy History\/Revision Information":"Annual Review Multiple Myeloma. 7\/1\/2024\nRemoved (1) 'Documentation of an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1', (2) 'Does not have central nervous system involvement with myeloma', (3) Does not have presence or history of plasma cell leukemia, (4) Removed Hematologist from specialist, (5) Documented diagnosis of multiple myeloma Conditions Not Covered.\nRemoved \u00e2\u20ac\u02dcRepeat administration of Idecabtagene vicleucel (Abecma), note that it was added to approve as a single dose in the criteria\nSelected Revision Multiple Myeloma: Requirement that the patient 8\/1\/2024\nhas received four or more lines of systemic therapy was revised to patient has received two or more lines of systemic therapy.\nAnnual Revision Multiple Myeloma: Added patient has received at 6\/1\/2025\nleast three prior lines of therapy as a new option for approval.\nUpdated HCPCS\/CPT Coding\nAdded code deleted note to CPT Codes: 0537T, 0538T, 0539T, 0540T (Codes deleted 12\/31\/2024)\nAdded CPT Codes: 38225, 38226, 38227, 38228\nUpdated the description for HCPCS Q2055 to match the 2024 revision.",
    "Conclusion":"Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy, indicated for the treatment of relapsed or refractory multiple myeloma in adults after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Cigna considers Abecma medically necessary for patients 18 years or older who have received at least two prior lines of systemic therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, or at least three prior lines of therapy, and who are planning to receive lymphodepleting chemotherapy prior to infusion of Abecma, and have not been previously treated with any CAR-T therapy. The medication must be prescribed by or in consultation with an oncologist. The dose of Abecma is up to 460 x 106 CAR-positive T-cells administered intravenously as a single dose. Abecma for any other use is considered not medically necessary. HCPCS code Q2055 and CPT codes 38225, 38226, 38227, and 38228 are associated with Abecma administration. The policy is currently active and was last updated on 2025-06-01.",
    "link":"https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0168_coveragepositioncriteria_idecabtagene_vicleucel.pdf"
  },
  {
    "Insurer":"Cigna",
    "HCPCS Code":"J0791",
    "Active Ingredient":"Crizanlizumab",
    "Brand Name":"Adakveo",
    "Therapeutic area":"Blood disorders",
    "indication":"Sickle-cell syndrome",
    "indicated_population":"Sickle-cell syndrome (in prevention of recurrent painful vaso-occlusive crises, in 16 years and older)",
    "Label Population":"1. Sickle Cell Disease. Approve for 1 year if the patient meets ONE of the following (A or B):\nA) Initial Therapy. Approve if the patient meets ALL of the following (i, ii, iii, and iv):\ni. Patient is \u2265 16 years of age; AND\nii. Patient has had at least one sickle cell-related crisis in the previous 12-month period; AND\niii. Patient meets ONE of the following (a, b, or c):\na) Patient is currently receiving a hydroxyurea product; OR\nb) According to the prescriber, patient has tried a hydroxyurea product and has experienced inadequate efficacy or significant intolerance; OR\nc) According to the prescriber, patient is not a candidate for hydroxyurea therapy; AND\nNote: Examples of patients who are not candidates for hydroxyurea therapy include patients who are pregnant or who are planning to become pregnant and patients with an immunosuppressive condition (such as cancer).\niv. The medication is prescribed by or in consultation with a physician who specializes in sickle cell disease (e.g., a hematologist).\nB) Patient is Currently Receiving Adakveo. Approve if the patient meets ALL of the following (i, ii, and iii):\ni. Patient is \u2265 16 years of age; AND\nii. According to the prescriber, patient is receiving clinical benefit from Adakveo therapy; AND\nNote: Examples of clinical benefit include reduction in the number of vasoocclusive crises\/sickle cell-related crises; delay in time to sickle cell-related crises; and reduction in the number of days in the hospital.\niii. The medication is prescribed by or in consultation with a physician who specializes in sickle cell disease (e.g., a hematologist).\nDosing. Approve the following dosing regimens (A and B):\nA) Up to 5 mg\/kg given by intravenous infusion at Weeks 0 and 2; AND\nB) Up to 5 mg\/kg given by intravenous infusion for up to once every 4 weeks.",
    "clinical_criteria":"Adakveo is considered medically necessary when the following criteria are met:\nFDA-Approved indication\n1. Sickle Cell Disease. Approve for 1 year if the patient meets ONE of the following (A or B):\nA) Initial Therapy. Approve if the patient meets ALL of the following (i, ii, iii, and iv):\ni. Patient is \u2265 16 years of age; AND\nii. Patient has had at least one sickle cell-related crisis in the previous 12-month period; AND\niii. Patient meets ONE of the following (a, b, or c):\na) Patient is currently receiving a hydroxyurea product; OR\nb) According to the prescriber, patient has tried a hydroxyurea product and has experienced inadequate efficacy or significant intolerance; OR\nc) According to the prescriber, patient is not a candidate for hydroxyurea therapy; AND\nNote: Examples of patients who are not candidates for hydroxyurea therapy include patients who are pregnant or who are planning to become pregnant and patients with an immunosuppressive condition (such as cancer).\niv. The medication is prescribed by or in consultation with a physician who specializes in sickle cell disease (e.g., a hematologist).\nB) Patient is Currently Receiving Adakveo. Approve if the patient meets ALL of the following (i, ii, and iii):\ni. Patient is \u2265 16 years of age; AND\nii. According to the prescriber, patient is receiving clinical benefit from Adakveo therapy; AND\nNote: Examples of clinical benefit include reduction in the number of vasoocclusive crises\/sickle cell-related crises; delay in time to sickle cell-related crises; and reduction in the number of days in the hospital.\niii. The medication is prescribed by or in consultation with a physician who specializes in sickle cell disease (e.g., a hematologist).\nDosing. Approve the following dosing regimens (A and B):\nA) Up to 5 mg\/kg given by intravenous infusion at Weeks 0 and 2; AND\nB) Up to 5 mg\/kg given by intravenous infusion for up to once every 4 weeks.\nWhen coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.\nReceipt of sample product does not satisfy any criteria requirements for coverage.",
    "Prior Authorisation\/Medical necessity\/notification":"No",
    "Preferred product(s) required":null,
    "Site of care required":"Yes",
    "Exclusion Criteria":"No specific exclusion criteria detailed. Document states: 'Any other use is considered experimental, investigational, or unproven (criteria will be updated as new published data are available)'. The document does not provide specific information about which patients, diagnoses, or clinical scenarios are excluded from coverage.",
    "Policy History\/Revision Information":"Annual Revision Policy Name Change: Updated Policy Name from 08\/01\/2024\n\u201cCrizanlizumab-tmca\u201d to \u201cSickle Cell Disease \u2013\nAdakveo.\u201d\nInitial Therapy: Replaced the requirement \u201cvaso-\nocclusive crisis (VOC)\u201d in the previous 12-month\nperiod\u201d with \u201csickle cell-related crisis\u201d. Added a\nnote detailing examples of patients ineligible for\nhydroxyurea therapy.\nPatient is Currently Receiving Adakveo: Added\nnote with examples of clinical benefit.\nConditions Not Covered: Removed \u201cConcomitant\nOxbryta Therapy.\u201d\nAnnual Revision No criteria changes. 4\/15\/2025",
    "Conclusion":"Adakveo (crizanlizumab-tmca) is a monoclonal antibody used to reduce the frequency of vasoocclusive crises due to sickle cell disease in patients 16 years and older. Cigna covers Adakveo for patients \u2265 16 years of age with at least one sickle cell-related crisis in the previous 12 months, who are either currently receiving hydroxyurea, have tried and experienced inadequate efficacy or intolerance to hydroxyurea, or are not candidates for hydroxyurea therapy. Patients currently receiving Adakveo must be receiving clinical benefit from the therapy. The medication must be prescribed by or in consultation with a physician who specializes in sickle cell disease. The approved dosing is up to 5 mg\/kg given by intravenous infusion at Weeks 0 and 2, and then up to 5 mg\/kg given by intravenous infusion for up to once every 4 weeks. Any other use is considered experimental, investigational, or unproven. HCPCS, ICD, and CPT coding information are not available in the document. The prior authorization process and timeline are not specified. Monitoring and continuation requirements are that the patient is receiving clinical benefit from Adakveo therapy. The document is active and was last revised on 4\/15\/2025.",
    "link":"https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0120_coveragepositioncriteria_crizanlizumab_tmca.pdf"
  },
  {
    "Insurer":"Cigna",
    "HCPCS Code":"J7171",
    "Active Ingredient":"Recombinant ADAMTS13",
    "Brand Name":"Adzynma",
    "Therapeutic area":"Autoimmune disorders",
    "indication":"Thrombotic Thrombocytopenic Purpura",
    "indicated_population":"TTP (congenital, prophylactic or on-demand ERT)",
    "Label Population":"Adzynma is considered medically necessary when the following criteria are met:\nFDA-Approved indication\n1. Congenital Thrombotic Thrombocytopenic Purpura. Approve for 1 year if the patient meets the following (A, B, C, and D):\nA) At baseline (prior to therapy) ADAMTS13 activity is < 10% (< 10 IU\/dL);\nNote: Baseline refers to before any treatment was received, such as Adzynma or plasma-based therapies.\nB) Patient does not have anti-ADAMTS13 autoantibodies as determined by a diagnostic test; AND\nC) Patient has a pathogenic variant or a mutation in the ADAMTS13 gene;\nNote: Pathogenic variants or gene mutations are usually homozygous or compound heterozygous.\nD) Medication is prescribed by or in consultation with a hematologist.\nDosing. Approve the following dosing regimens (A and\/or B):\nA) Routine prophylaxis: approve up to 40 IU\/kg by intravenous infusion once weekly; AND\/OR\nB) On demand therapy: approve up to 135 IU\/kg by intravenous infusion per week as needed for the treatment of acute event(s).\nNote: On demand therapy is given as a daily dose until 2 days after the acute event resolves; however, the total weekly dose should not exceed 135 IU\/kg.",
    "clinical_criteria":"Adzynma is considered medically necessary when the following criteria are met:\nFDA-Approved indication\n1. Congenital Thrombotic Thrombocytopenic Purpura. Approve for 1 year if the patient meets the following (A, B, C, and D):\nA) At baseline (prior to therapy) ADAMTS13 activity is < 10% (< 10 IU\/dL);\nNote: Baseline refers to before any treatment was received, such as Adzynma or plasma-based therapies.\nB) Patient does not have anti-ADAMTS13 autoantibodies as determined by a diagnostic test; AND\nC) Patient has a pathogenic variant or a mutation in the ADAMTS13 gene;\nNote: Pathogenic variants or gene mutations are usually homozygous or compound heterozygous.\nD) Medication is prescribed by or in consultation with a hematologist.\nDosing. Approve the following dosing regimens (A and\/or B):\nA) Routine prophylaxis: approve up to 40 IU\/kg by intravenous infusion once weekly; AND\/OR\nB) On demand therapy: approve up to 135 IU\/kg by intravenous infusion per week as needed for the treatment of acute event(s).\nNote: On demand therapy is given as a daily dose until 2 days after the acute event resolves; however, the total weekly dose should not exceed 135 IU\/kg.\n\nWhen coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.\nReceipt of sample product does not satisfy any criteria requirements for coverage.",
    "Prior Authorisation\/Medical necessity\/notification":"No",
    "Preferred product(s) required":null,
    "Site of care required":"No",
    "Exclusion Criteria":"Any other use is considered experimental, investigational, or unproven (criteria will be updated as new published data are available).",
    "Policy History\/Revision Information":"New: New policy. 5\/01\/2024\nAnnual Revision: No criteria changes. 3\/1\/2025",
    "Conclusion":"Adzynma (ADAMTS13 recombinant-krhn) is a human recombinant product indicated for prophylactic or on-demand enzyme replacement therapy for congenital thrombotic thrombocytopenia purpura in adult and pediatric patients. Cigna considers Adzynma medically necessary for patients with congenital thrombotic thrombocytopenic purpura when the patient has ADAMTS13 activity < 10% at baseline, does not have anti-ADAMTS13 autoantibodies, has a pathogenic variant or mutation in the ADAMTS13 gene, and the medication is prescribed by or in consultation with a hematologist. The approved dosing regimens are up to 40 IU\/kg by intravenous infusion once weekly for routine prophylaxis, and up to 135 IU\/kg by intravenous infusion per week as needed for on-demand therapy. Any other use is considered experimental, investigational, or unproven. The HCPCS code for Adzynma is J7171. The document status is active and the effective date is 2025-03-01. Quantity limits and dispensing restrictions are not available.",
    "link":"https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0606_coveragepositioncriteria_adzynma.pdf"
  },
  {
    "Insurer":"Cigna",
    "HCPCS Code":"J0225",
    "Active Ingredient":"Vutrisiran",
    "Brand Name":"Amvuttra",
    "Therapeutic area":"Genetic disorders",
    "indication":"Amyloidosis",
    "indicated_population":"hATTR amyloidosis (polyneuropathy, in adults)",
    "Label Population":"1. Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis (hATTR). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nA) Patient is \u226518 years of age; AND\nB) Documentation provided that the patient has a transthyretin pathogenic variant as confirmed by genetic testing; AND\nC) Documentation provided that the patient has symptomatic polyneuropathy; AND\nNote: Examples of symptomatic polyneuropathy include reduced motor strength\/coordination, and impaired sensation (e.g., pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing.\nD) Patient does not have a history of liver transplantation; AND\nE) The medication is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.\n2. Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nNote: Variant Transthyretin Amyloidosis is also known as Hereditary Transthyretin Amyloidosis.\nA) Patient is \u2265 18 years of age; AND\nB) Documentation provided that the diagnosis was confirmed by ONE of the following (i, ii, or iii):\ni. A technetium pyrophosphate scan (i.e., nuclear scintigraphy); OR\nii. A tissue biopsy with confirmatory transthyretin (TTR) amyloid typing by mass spectrometry, immunoelectron microscopy, or immunohistochemistry; OR\niii. Patient had genetic testing which, according to the prescriber, identified a transthyretin (TTR) pathogenic variant; AND\nNote: Examples of TTR variants include Val122Ile variant and Thr60Ala variant. If the patient has wild-type amyloidosis, this is not a TTR pathogenic variant.\nC) Diagnostic cardiac imaging has demonstrated cardiac involvement; AND\nNote: Examples of cardiac imaging include echocardiogram and cardiac magnetic imaging. Examples of cardiac involvement on imaging include increased thickness of the ventricular wall or interventricular septum.\nD) Patient has heart failure, but does not have New York Heart Association class IV disease; AND\nE) The medication is prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.",
    "clinical_criteria":"Amvuttra is considered medically necessary when the following are met:\nFDA-Approved indication\n1. Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis (hATTR). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nA) Patient is \u226518 years of age; AND\nB) Documentation provided that the patient has a transthyretin pathogenic variant as confirmed by genetic testing; AND\nC) Documentation provided that the patient has symptomatic polyneuropathy; AND\nNote: Examples of symptomatic polyneuropathy include reduced motor strength\/coordination, and impaired sensation (e.g., pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing.\nD) Patient does not have a history of liver transplantation; AND\nE) The medication is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.\n2. Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nNote: Variant Transthyretin Amyloidosis is also known as Hereditary Transthyretin Amyloidosis.\nA) Patient is \u2265 18 years of age; AND\nB) Documentation provided that the diagnosis was confirmed by ONE of the following (i, ii, or iii):\ni. A technetium pyrophosphate scan (i.e., nuclear scintigraphy); OR\nii. A tissue biopsy with confirmatory transthyretin (TTR) amyloid typing by mass spectrometry, immunoelectron microscopy, or immunohistochemistry; OR\niii. Patient had genetic testing which, according to the prescriber, identified a transthyretin (TTR) pathogenic variant; AND\nNote: Examples of TTR variants include Val122Ile variant and Thr60Ala variant. If the patient has wild-type amyloidosis, this is not a TTR pathogenic variant.\nC) Diagnostic cardiac imaging has demonstrated cardiac involvement; AND\nNote: Examples of cardiac imaging include echocardiogram and cardiac magnetic imaging. Examples of cardiac involvement on imaging include increased thickness of the ventricular wall or interventricular septum.\nD) Patient has heart failure, but does not have New York Heart Association class IV disease; AND\nE) The medication is prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.\nWhen coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.",
    "Prior Authorisation\/Medical necessity\/notification":"No",
    "Preferred product(s) required":null,
    "Site of care required":"Yes",
    "Exclusion Criteria":"Amvuttra for any other use is considered not medically necessary, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):\n1. Concurrent use with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Attruby [acoramidis tablets], Onpattro [patisiran intravenous infusion], Tegsedi [inotersen subcutaneous injection], Wainua [eplontersen subcutaneous injection], or a tafamidis product).\nThe requested medication should not be administered in combination with other medications indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy. Combination therapy is generally not recommended due to a lack of controlled clinical trial data supporting additive efficacy.",
    "Policy History\/Revision Information":"Annual Review Polyneuropathy of Hereditary Transthyretin\u2013Mediated Amyloidosis (hATTR). 10\/1\/2024\nRemoved \u2018Documentation that other causes of neuropathy have been excluded (for example, diabetes)\u2019\nUpdated \u2018Documented diagnosis of hereditary transthyretin-mediated (hATTR) amyloidosis confirmed by a transthyretin (TTR) genetic variant (pathogenic or likely pathogenic variant)\u2019 to \u2018Patient has a transthyretin pathogenic variant as confirmed by genetic testing\u2019\nUpdated \u2018Documentation of symptomatic polyneuropathy confirmed by history and clinical exam, electromyography, or nerve conduction velocity\u2019 to \u2018Patient has symptomatic polyneuropathy; Note: Examples of symptomatic polyneuropathy include reduced motor strength\/coordination, and impaired sensation (e.g., pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing.\u2019\nAdded to dosing \u2018The dose is administered not more frequently than once every 3 months.\u2019\nConditions Not Covered.\nRemoved (1) Treatment of Cardiomyopathy hATTR in the Absence of Polyneuropathy Symptoms, (2) Treatment of Polyneuropathy Not Related to hATTR Amyloidosis.\nUpdated title from \u201cVutrisiran\u2019 to \u2018Amyloidosis \u2013 Amvuttra\u2019\nAnnual Revision Added \u201cDocumentation: Documentation is required where noted in the criteria. Documentation may include, but not limited to, chart notes, laboratory tests, medical test results, genetic test results, claims records, and\/or other information.\u201d 3\/1\/2025\nPolyneuropathy of Hereditary Transthyretin\u2013Mediated Amyloidosis (hATTR)\nUpdated criteria from \u201cPatient has a transthyretin pathogenic variant as confirmed by genetic testing\u201d to \u201cDocumentation provided that the patient has a transthyretin pathogenic variant as confirmed by genetic testing.\u201d\nUpdated criteria from \u201cPatient has symptomatic polyneuropathy\u201d to \u201cDocumentation provided that the patient has symptomatic polyneuropathy.\u201d\nConditions Not Covered\nConcurrent use with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Attruby (acoramidis tablets), Onpattro (patisiran intravenous infusion), Tegsedi (inotersen subcutaneous injection), Wainua (eplontersen subcutaneous injection), or a tafamidis product) was changed to as listed (previously, concomitant use with Onpattro [patisiran intravenous injection], Tegsedi [inotersen subcutaneous injection], Wainua [eplontersen subcutaneous injection, or a Tafamidis product was listed.)\nAnnual Revision Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM): This condition and criteria for approval were added to the policy. 6\/1\/2025",
    "Conclusion":"Amvuttra (vutrisiran) is a transthyretin (TTR)-directed small interfering RNA. It is indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalization, and urgent heart failure visits. Cigna covers Amvuttra for these indications when specific criteria are met, including age \u226518 years, confirmed diagnosis via genetic testing or other methods, presence of symptomatic polyneuropathy or heart failure (but not NYHA class IV), and prescription by a specialist. The dosage is 25 mg by subcutaneous injection, administered not more frequently than once every 3 months. Exclusions include concurrent use with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy. HCPCS code J0225 is available for vutrisiran injection. ICD and CPT codes are not available in the document. Prior authorization is required. The document was updated on June 1, 2025, to include criteria for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).",
    "link":"https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0478_coveragepositioncriteria_vutrisiran.pdf"
  },
  {
    "Insurer":"Cigna",
    "HCPCS Code":"J0225",
    "Active Ingredient":"Vutrisiran",
    "Brand Name":"Amvuttra",
    "Therapeutic area":"Genetic disorders",
    "indication":"Amyloidosis",
    "indicated_population":"Amyloidosis (with wild-type or hATTR cardiomyopathy, adults)",
    "Label Population":"1. Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis (hATTR). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nA) Patient is \u226518 years of age; AND\nB) Documentation provided that the patient has a transthyretin pathogenic variant as confirmed by genetic testing; AND\nC) Documentation provided that the patient has symptomatic polyneuropathy; AND\nNote: Examples of symptomatic polyneuropathy include reduced motor strength\/coordination, and impaired sensation (e.g., pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing.\nD) Patient does not have a history of liver transplantation; AND\nE) The medication is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.\n2. Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nNote: Variant Transthyretin Amyloidosis is also known as Hereditary Transthyretin Amyloidosis.\nA) Patient is \u2265 18 years of age; AND\nB) Documentation provided that the diagnosis was confirmed by ONE of the following (i, ii, or iii):\ni. A technetium pyrophosphate scan (i.e., nuclear scintigraphy); OR\nii. A tissue biopsy with confirmatory transthyretin (TTR) amyloid typing by mass spectrometry, immunoelectron microscopy, or immunohistochemistry; OR\niii. Patient had genetic testing which, according to the prescriber, identified a transthyretin (TTR) pathogenic variant; AND\nNote: Examples of TTR variants include Val122Ile variant and Thr60Ala variant. If the patient has wild-type amyloidosis, this is not a TTR pathogenic variant.\nC) Diagnostic cardiac imaging has demonstrated cardiac involvement; AND\nNote: Examples of cardiac imaging include echocardiogram and cardiac magnetic imaging. Examples of cardiac involvement on imaging include increased thickness of the ventricular wall or interventricular septum.\nD) Patient has heart failure, but does not have New York Heart Association class IV disease; AND\nE) The medication is prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.",
    "clinical_criteria":"Amvuttra is considered medically necessary when the following are met:\nFDA-Approved indication\n1. Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis (hATTR). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nA) Patient is \u226518 years of age; AND\nB) Documentation provided that the patient has a transthyretin pathogenic variant as confirmed by genetic testing; AND\nC) Documentation provided that the patient has symptomatic polyneuropathy; AND\nNote: Examples of symptomatic polyneuropathy include reduced motor strength\/coordination, and impaired sensation (e.g., pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing.\nD) Patient does not have a history of liver transplantation; AND\nE) The medication is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.\n2. Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM). Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):\nNote: Variant Transthyretin Amyloidosis is also known as Hereditary Transthyretin Amyloidosis.\nA) Patient is \u2265 18 years of age; AND\nB) Documentation provided that the diagnosis was confirmed by ONE of the following (i, ii, or iii):\ni. A technetium pyrophosphate scan (i.e., nuclear scintigraphy); OR\nii. A tissue biopsy with confirmatory transthyretin (TTR) amyloid typing by mass spectrometry, immunoelectron microscopy, or immunohistochemistry; OR\niii. Patient had genetic testing which, according to the prescriber, identified a transthyretin (TTR) pathogenic variant; AND\nNote: Examples of TTR variants include Val122Ile variant and Thr60Ala variant. If the patient has wild-type amyloidosis, this is not a TTR pathogenic variant.\nC) Diagnostic cardiac imaging has demonstrated cardiac involvement; AND\nNote: Examples of cardiac imaging include echocardiogram and cardiac magnetic imaging. Examples of cardiac involvement on imaging include increased thickness of the ventricular wall or interventricular septum.\nD) Patient has heart failure, but does not have New York Heart Association class IV disease; AND\nE) The medication is prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis.\nDosing. Approve the following dosing regimen (A and B):\nA) The dose is 25 mg by subcutaneous injection; AND\nB) The dose is administered not more frequently than once every 3 months.\nWhen coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.",
    "Prior Authorisation\/Medical necessity\/notification":"No",
    "Preferred product(s) required":null,
    "Site of care required":"Yes",
    "Exclusion Criteria":"Amvuttra for any other use is considered not medically necessary, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):\n1. Concurrent use with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Attruby [acoramidis tablets], Onpattro [patisiran intravenous infusion], Tegsedi [inotersen subcutaneous injection], Wainua [eplontersen subcutaneous injection], or a tafamidis product).\nThe requested medication should not be administered in combination with other medications indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy. Combination therapy is generally not recommended due to a lack of controlled clinical trial data supporting additive efficacy.",
    "Policy History\/Revision Information":"Annual Review Polyneuropathy of Hereditary Transthyretin\u2013Mediated Amyloidosis (hATTR). 10\/1\/2024\nRemoved \u2018Documentation that other causes of neuropathy have been excluded (for example, diabetes)\u2019\nUpdated \u2018Documented diagnosis of hereditary transthyretin-mediated (hATTR) amyloidosis confirmed by a transthyretin (TTR) genetic variant (pathogenic or likely pathogenic variant)\u2019 to \u2018Patient has a transthyretin pathogenic variant as confirmed by genetic testing\u2019\nUpdated \u2018Documentation of symptomatic polyneuropathy confirmed by history and clinical exam, electromyography, or nerve conduction velocity\u2019 to \u2018Patient has symptomatic polyneuropathy; Note: Examples of symptomatic polyneuropathy include reduced motor strength\/coordination, and impaired sensation (e.g., pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing.\u2019\nAdded to dosing \u2018The dose is administered not more frequently than once every 3 months.\u2019\nConditions Not Covered.\nRemoved (1) Treatment of Cardiomyopathy hATTR in the Absence of Polyneuropathy Symptoms, (2) Treatment of Polyneuropathy Not Related to hATTR Amyloidosis.\nUpdated title from \u201cVutrisiran\u2019 to \u2018Amyloidosis \u2013 Amvuttra\u2019\nAnnual Revision Added \u201cDocumentation: Documentation is required where noted in the criteria. Documentation may include, but not limited to, chart notes, laboratory tests, medical test results, genetic test results, claims records, and\/or other information.\u201d 3\/1\/2025\nPolyneuropathy of Hereditary Transthyretin\u2013Mediated Amyloidosis (hATTR)\nUpdated criteria from \u201cPatient has a transthyretin pathogenic variant as confirmed by genetic testing\u201d to \u201cDocumentation provided that the patient has a transthyretin pathogenic variant as confirmed by genetic testing.\u201d\nUpdated criteria from \u201cPatient has symptomatic polyneuropathy\u201d to \u201cDocumentation provided that the patient has symptomatic polyneuropathy.\u201d\nConditions Not Covered\nConcurrent use with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Attruby (acoramidis tablets), Onpattro (patisiran intravenous infusion), Tegsedi (inotersen subcutaneous injection), Wainua (eplontersen subcutaneous injection), or a tafamidis product) was changed to as listed (previously, concomitant use with Onpattro [patisiran intravenous injection], Tegsedi [inotersen subcutaneous injection], Wainua [eplontersen subcutaneous injection, or a Tafamidis product was listed.)\nAnnual Revision Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM): This condition and criteria for approval were added to the policy. 6\/1\/2025",
    "Conclusion":"Amvuttra (vutrisiran) is a transthyretin (TTR)-directed small interfering RNA. It is indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalization, and urgent heart failure visits. Cigna covers Amvuttra for these indications when specific criteria are met, including age \u226518 years, confirmed diagnosis via genetic testing or other methods, presence of symptomatic polyneuropathy or heart failure (but not NYHA class IV), and prescription by a specialist. The dosage is 25 mg by subcutaneous injection, administered not more frequently than once every 3 months. Exclusions include concurrent use with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy. HCPCS code J0225 is available for vutrisiran injection. ICD and CPT codes are not available in the document. Prior authorization is required. The document was updated on June 1, 2025, to include criteria for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).",
    "link":"https:\/\/static.cigna.com\/assets\/chcp\/pdf\/coveragePolicies\/pharmacy\/ip_0478_coveragepositioncriteria_vutrisiran.pdf"
  }
]